GlaxoSmithKline Pakistan (KAR:GLAXO) Moat Score: 0/10 (As of Jul. 03, 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
92 GF Score
Price ₨376.99
GF Value ₨324.20
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Moat Score?

GlaxoSmithKline Pakistan has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

GlaxoSmithKline Pakistan has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes GlaxoSmithKline Pakistan might have No Moat - No discernible moat.

GlaxoSmithKline Pakistan  (KAR:GLAXO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

GlaxoSmithKline Pakistan Moat Score Related Terms

KAR:GLAXO
92GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨376.99 is trading 16.3% above its estimated GF Value™ of ₨324.20. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Moat Score: 0
  • GF Value™: ₨324.20 vs. price of ₨376.99 (16.3% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score

Get the complete analysis for KAR:GLAXO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨376.99
Price
₨324.20
GF Value